ethacrynic acid NDC 68682-011

NDC codes

FDA NDC Directory

Product NDC (as listed)68682-011Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68682-0011Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68682-011-10	68682001110	100 TABLET in 1 BOTTLE (68682-011-10)Marketed from Jan 10, 1967

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): ethacrynic acid
Generic name (nonproprietary): ethacrynic acid
Active ingredients: Ethacrynic acid — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Oceanside Pharmaceuticals
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 016092
Marketing start: Jan 10, 1967
Listing expires: Dec 31, 2026
Other FDA classes: Increased Diuresis at Loop of Henle (Physiologic effect)
Identifiers: Product ID 68682-011_4c621e16-3dbb-4774-935e-69270e52fe8eSPL ID 4c621e16-3dbb-4774-935e-69270e52fe8eSPL set ID f127598f-e6b3-4c35-800f-76e4217595aeRxCUI 617325, 1251903UNII M5DP350VZVUPC 0368682011104
Pharmacologic class: Loop Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468682001110 followed by a unit qualifier and the quantity

Package 68682-0011-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 31, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impai…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 016092

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 016092
Product	Strength	Form · route	Labeler	Product NDC
Edecrinethacrynic acid	Ethacrynic acid 25 mg/1	TabletOral	Bausch Health US, LLC	25010-215